Pathophysiological mechanisms of death resistance in colorectal carcinoma

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11777-11792

  Huang, Ching Ying ^a   Linda, Chia Hui Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti apoptosis; Anti necroptosis; Chemoresistance; Colon cancer; Cytoprotection; Tumorigenesis

Indexed keywords

APC PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; GLUCOSE; GLUCOSE TRANSPORTER; GROWTH FACTOR; PROSTAGLANDIN E2; PROTEIN P53; TOLL LIKE RECEPTOR 4; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; GENE INACTIVATION; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE FUNCTION; INTRACELLULAR SIGNALING; NECROPTOSIS; NONHUMAN; PARACRINE SIGNALING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TURNOVER TIME; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NECROSIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84947246914     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11777     Document Type: Article

References (160)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 [PMID: 10647931]
2. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaría G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674-6681 [PMID: 12438266]
3. Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 2015; Epub ahead of print [PMID: 25936818 DOI: 10.1016/j.semcancer.2015.03.001]
4. Viry E, Paggetti J, Baginska J, Mgrditchian T, Berchem G, Moussay E, Janji B. Autophagy: an adaptive metabolic response to stress shaping the antitumor immunity. Biochem Pharmacol 2014; 92: 31-42 [PMID: 25044308 DOI: 10.1016/j.bcp.2014.07.006]
5. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 2009; 15: 225-233 [PMID: 19362056 DOI: 10.1016/j.molmed.2009.03.003]
6. Loktionov A. Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Can cer 2007; 120: 2281-2289 [PMID: 17351899 DOI: 10.1002/ijc.22647]
7. Humphries F, Yang S, Wang B, Moynagh PN. RIP kinases: key decision makers in cell death and innate immunity. Cell Death Differ 2015; 22: 225-236 [PMID: 25146926 DOI: 10.1038/cdd.2014.126]
8. Günther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 2013; 62: 1062-1071 [PMID: 22689519 DOI: 10.1136/gutjnl-2011-301364]
9. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000; 50: 273-279 [PMID: 10849312]
10. Zhang L, Yu J. Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep 2013; 9 [PMID: 24273467 DOI: 10.1007/s11888-013-0188-z]
11. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms o f necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714 [PMID: 20823910]
12. Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P. Major cell death pathways at a glance. Microbes Infect 2009; 11: 1050-1062 [PMID: 19733681]
13. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3: re4 [PMID: 20354226]
14. Marshall KD, Baines CP. Necroptosis: is there a role for mitochondria Front Physiol 2014; 5: 323 [PMID: 25206339 DOI: 10.3389/fphys.2014.00323]
15. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009; 138: 229-232 [PMID: 19632174]
16. Linkermann A,Green DR. Necroptosis N Engl J Med 2014 370 455-465 PMID: 24476434 DOI: 10.1056/NEJMra1310050]
17. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N , Guerin CJ, Brunk UT, Declercq W, Vandenabeele P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 922-930 [PMID: 20010783]
18. Sosna J, Voigt S, Mathieu S, Lange A, Thon L, Davarnia P, Herdegen T, Linkermann A, Rittger A, Chan FK, Kabelitz D, Schütze S, Adam D. TNF-induced necroptosis and PARP-1-mediated nec rosis represent distinct routes to programmed necrotic cell death. Cell Mol Life Sci 2014; 71: 331-348 [PMID: 23760205 DOI: 10.1007/s00018-013-1381-6]
19. Huang CY, Kuo WT, Huang YC, Le e TC, Yu LC. Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. Cell Death Dis 2013; 4: e622 [PMID: 23640464 DOI: 10.1038/cddis. 2013.149]
20. Yen TH, Wright NA. The gastrointestinal tract stem cell niche. Stem Cell Rev 2006; 2: 203-212 [PMID: 17625256]
21. Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol 2012; 3: 27-43 [PMID: 22368784 DOI: 10.4291/wjgp.v3.i1.27]
22. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-1816 [PMID: 7728743]
23. Duckworth CA, Pritchard DM. Suppression of apoptosis, crypt hyperplasia, and altered differentiation in the colonic epithelia of bak-null mice. Gastroenterology 2009; 136: 943-952 [PMID: 19185578 DOI: 10.1053/j.gastro.2008.11.036]
24. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, Lee JR, Liu K. NF-?B directly regulates F as transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 2012; 287: 25530-25540 [PMID: 22669972 DOI: 10.1074/jbc.M112.356279]
25. Qiu W, Carson-Walter EB, Kuan SF, Zhang L, Yu J. PUMA suppresses intestinal tumorigenesis in mice. Cancer Res 2009; 69: 4999-5006 [PMID: 19491259 DOI: 10.1158/0008-5472. CAN-09-0262]
26. Scheepers A, Joost HG, Schürmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004; 28: 364-371 [PMID: 15449578]
27. Godoy A, Ulloa V, Rodr íguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006; 207: 614-627 [PMID: 16523487 DOI: 10.1002/jcp.20606]
28. Huang CY, Hsiao JK, Lu YZ, Lee TC, Yu LC. Anti-Apoptotic PI3K/Akt signaling by sodium/glucose transporter 1 reduces epithelial barrier damage and bacterial translocation in intestinal ischemia. Lab Invest 2011; 91: 294-309 [PMID: 20975661]
29. Yu LC, Flynn AN, Turner JR, Buret AG. SGLT-1-mediated glucose uptake protects intestinal epi thelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism? FASEB J 2005; 19: 1822-1835 [PMID: 16260652]
30. Yu LC, Huang CY, Kuo WT, Sayer H, Turner JR, Buret AG. SGLT-1-mediated glucose uptake protects human intestinal epithelial cells against Giardia duodenalis-induced apoptosis. Int J Parasitol 2008; 38: 923-934 [PMID: 18281046]
31. Palazzo M, G ariboldi S, Zanobbio L, Selleri S, Dusio GF, Mauro V, Rossini A, Balsari A, Rumio C. Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa. J Immunol 2008; 181: 3126-3136 [PMID: 18713983]
32. Kallweit AR, Baird CH, Stutzman DK, Wischmeyer PE. Glutamine prevents apoptosis in intestinal epithelial cells and induces differential protective pathways in heat and oxidant inju ry models. JPEN J Parenter Enteral Nutr 2012; 36: 551-555 [PMID: 22544840 DOI: 10.1177/0148607112445579]
33. Haynes TE, Li P, Li X, Shimotori K, Sato H, Flynn NE, Wang J, Knabe DA, Wu G. L-Glutamine or L-Alanyl-L-glutamine prevents oxidant-or endotoxin-induced death of neonatal enterocytes. Amino Acids 2009; 37: 131-142 [PMID: 19189199 DOI: 10.1007/s00726-009-0243-x]
34. Ban K, Kozar RA. Glutamine protects against apoptosis via downregulation of Sp3 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1344-G1353 [PMID: 20884886 DOI: 10.1152/ajpgi.00334.2010]
35. Sakiyama T, Musch MW, Ropeleski MJ, Tsubouchi H, Chang EB. Glutamine increases autophagy under Basal and stressed conditions in intestinal epithelial cells. Gastroenterology 2009; 136: 924-932 [PMID: 19121316 DOI: 10.1053/j.gastro.2008.12.002]
36. Evans ME, Jones DP, Ziegler TR. Glutamine inhibits cytokineinduced apoptosis in human colonic epithelial cells via the pyrimidine pathway. Am J Physiol Gastrointest Liver Physiol 2005; 289: G388-G396 [PMID: 15878985 DOI: 10.1152/ajpgi.00072.2005]
37. Ropeleski MJ,Riehm J,Baer KA,Musch MW,Chang EB. Anti-Apoptotic effects of L-glut amine-mediated transcriptional modulation of the heat shock protein 72 during heat shock Gastroenterology 2005 129 170-184 PMID: 16012946]
38. Riaz AA, Wan MX, Schäfer T, Dawson P, Menger MD, Jeppsson B, Thorlacius H. Allopurinol and superoxide dismutase protect against leucocyte-endothelium interactions in a novel model of colonic ischaemia-reperfusion. Br J Surg 2002; 89: 1572-1580 [PMID: 12445069]
39. Simpson R, Alon R, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion. Ann Surg 1993; 218: 444-53; discussion 453-4 [PMID: 8215636]
40. Sun Z, Olanders K, Lasson A, Dib M, Annborn M, Andersson K, Wang X, Andersson R. Effective treatment of gut barrier dysfunction using an antioxidant, a PAF inhibitor, and monoclonal antibodies against the adhesion m olecule PECAM-1. J Surg Res 2002; 105: 220-233 [PMID: 12121711]
41. Keely S, Campbell EL, Baird AW, Hansbro PM, Shalwitz RA, Kotsakis A, McNamee EN, Eltzschig HK, Kominsky DJ, Colgan SP. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis. Mucosal Immunol 2014; 7: 114-123 [PMID: 23695513 DOI: 10.1038/mi.2013.29]
42. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK. Hypoxia-inducible factor-1?-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol 2011; 186: 4367-4374 [PMID: 21357264 DOI: 10.4049/jimmunol.0903617]
43. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol 2010; 7: 281-287 [PMID: 20368740]
44. Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treat Rev 2015; 41: 623-633 [PMID: 25981453 DOI: 10.1016/j.ctrv.2015.05.004]
45. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713 [PMID: 19143055 DOI: 10.1038/nrc2468]
46. Hirota SA, Fines K, Ng J, Traboulsi D, Lee J, Ihara E, Li Y, Willmore WG, Chung D, Scully MM, Louie T, Medlicott S, Lejeune M, Chadee K, Armstrong G, Colgan SP, Muruve DA, MacDonald JA, Beck PL. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterolog y 2010; 139: 259-69.e3 [PMID: 20347817 DOI: 10.1053/j.gastro.2010.03.045]
47. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK, Colgan SP. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 2001; 193: 1027-1034 [PMID: 11342587]
48. Karhausen J, Furuta GT, T omaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098-1106 [PMID: 15489957]
49. Fuk ata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apopto sis in the intestine. Gastroenterology 2006; 131: 862-877 [PMID: 16952555]
50. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K. Aggravation by selective COX-1 and COX-2 inhib itors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 2007; 52: 2095-2103 [PMID: 17429720 DOI: 10.1007/s10620-006-9597-z]
51. Nishihara H, Kizaka-Kondoh S, Insel PA, Ec kmann L. Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 2003; 100: 8921-8926 [PMID: 12837940 DOI: 10. 1073/pnas.1533221100]
52. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006; 6: 350-354 [PMID: 16690355 DOI: 10.1016/j.coph.2006.01.009]
53. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-127 [PMID: 18154452 DOI: 10.2217/14622416.9.1.105]
54. Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 2011; 41: 175-182 [PMID: 21264751 DOI: 10.1007/s00595-010-4390-1]
55. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of su rvivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-2032 [PMID: 11391581]
56. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pa thol 2001; 158: 1289-1299 [PMID: 11290547 DOI: 10.1016/S0002-9440(10)64080-1]
57. Heijink DM, Kleibeuker JH, Jalving M, Boersma-van Ek W, Koornstra JJ, Wesseling J, de Jong S. Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. Cell Oncol 2007; 29: 409-419 [PMID: 17726263]
58. Xiang G, Wen X, Wang H, Chen K, Liu H. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 2009; 100: 708-712 [PMID: 19777490 DOI: 10.1002/jso.21408]
59. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S, Tsukamoto M, Thomas RG, Assa-Munt N, Piao Z, Suzuki K, Perucho M, Krajewski S, Reed JC. Analysis of apoptosis protein expre ssion in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005; 11: 5451-5461 [PMID: 16061861 DOI: 10.1158/1078-0432. CCR-05-0094]
60. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 2009; 100: 903-913 [PMID: 19302291 DOI: 10.1111/j.1349-7006.2009.01112.x]
61. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009; 24: 875-884 [PMID: 194217 58 DOI: 10.1007/s00384-009-0725-z]
62. Moriwaki K, Bertin J, Gough PJ, Orlowski GM, Chan FK. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis 2015; 6: e1636 [PMID: 25675296 DOI: 10.1038/cddis.2015.16]
63. Ewing I, Hurley JJ, Josephides E, Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol 2014; 5: 26-30 [PMID: 24416503 DOI: 10.1136/flgastro-2013-100329]
64. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013; 25: 177-183 [PMID: 23402869 DOI: 10.1016/j.ceb.2013.01.007]
65. Laurent-Puig P, Blons H, Cugnenc PH. Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 1999; 8 Suppl 1: S39-S47 [PMID: 10772417]
66. Katkoori VR, Shanmugam C, Jia X, Vitta SP, Sthanam M, Callens T, Messiaen L, Chen D, Zhang B, Bumpers HL, Samuel T, Manne U. Prognostic significance and gene expression profiles of p53 mutations in microsatellite-stable stage III colorectal adenocarcinomas. PLoS One 2012; 7: e30020 [PMID: 22276141 DOI: 10.1371/journal.pone.0030020]
67. Zamzami N, Kroemer G. p53 in apoptosis control: an introduction. Biochem Biophys Res Commun 2005; 331: 685-687 [PMID: 15865922 DOI: 10.1016/j.bbrc.2005.04.013]
68. Bedi A, Mookerjee B. Biological significance and molecular mechanisms of p53-induced apoptosis. Apoptosis 1998; 3: 237-244 [PMID: 14646487]
69. Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2010; 2: a001040 [PMID: 20452943 DOI: 10.1101/cshperspect.a001040]
70. Liu Y, Borchert GL, Surazynski A, Phang JM. Proline oxidase, a p53-induced gene, targe ts COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 2008; 27: 6729-6737 [PMID: 18794809 DOI: 10.1038/onc.2008.322]
71. Taketani K, Kawauchi J, Tanaka-Okamoto M, Ishizaki H, Tanaka Y, Sakai T, Miyoshi J, Maehara Y, Kitajima S. Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells. Oncogene 2012; 31: 2210-2221 [PMID: 21927023 DOI: 10.1038/onc.2011.397]
72. Edagawa M, Kawauchi J, Hirata M, Goshima H, Inoue M, Okamoto T, Murakami A, Maehara Y, Kitajima S. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL)-mediated apoptosis through upregulation of death receptor 5 (DR5) by zerumbone and celecoxib. J Biol Chem 2014; 289: 21544-21561 [PMID: 24939851 DOI: 10.1074/jbc.M114.558890]
73. Wang P, Qiu W, Dudgeon C, Liu H, Huang C, Zambetti GP, Yu J, Zhang L . PUMA is directly activated by NF-kappaB and contributes to TNF-Alpha-induced apoptosis. Cell Death Differ 2009; 16: 1192-1202 [PMID: 19444283 DOI: 10.1038/cdd.2009.51]
74. Singh AB, Shar ma A, Dhawan P. Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis 2012; 33: 2538-2547 [PMID: 22941059 DOI: 10.1093/carcin/bgs275]
75. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 2006; 130: 137-149 [PMID: 16401477 DOI: 10.1053/j.gastro.2005.10.001]
76. Raufman JP, Shant J, Guo CY, Roy S, Cheng K. Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol 2008; 215: 538-549 [PMID: 18064605 DOI: 10.1002/jcp.21332]
77. Khor TO, Gul YA, Ithnin H, Seow HF. Positive correlation between overexpression of phospho-BA D with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett 2004; 210: 139-150 [PMID: 15183529 DOI: 10.1016/j.canlet.2004.01.017]
78. Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Mol Cancer Ther 2013; 12: 2640-2650 [PMID: 24126433 DOI: 10.1158/1535-7163.MCT-13-0066]
79. Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG, Chowdhury S. Akt inhibitor MK-2206 promotes antitumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cance r 2014; 14: 145 [PMID: 24581231 DOI: 10.1186/1471-2407-14-145]
80. Huang CC,Wu DW,Lin PL,Lee H. Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabi lization of Bcl-2 protein by phosphorylation at Serine 87 Oncotarget 2015 6 8698-8708 PMID: 25826088]
81. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 an d Bcl-xL. EMBO J 2007; 26: 2856-2867 [PMID: 17525735 DOI: 10.1038/sj.emboj.7601723]
82. Yu LF, Wang J, Zou B, Lin MC, Wu YL, Xia HH, Sun YW, Gu Q, He H, Lam SK, Kung HF , Wong BC. XAF1 mediates apoptosis through an extracellular signal-regulated kinase pathway in colon cancer. Cancer 2007; 109: 1996-2003 [PMID: 17385215 DOI: 10.1002/cncr.22624]
83. Kanarek N, Lo ndon N, Schueler-Furman O, Ben-Neriah Y. Ubiquitination and degradation of the inhibitors of NF-kappaB. Cold Spring Harb Perspect Biol 2010; 2: a000166 [PMID: 20182612 DOI: 10.1101/cshperspect.a000166]
84. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-Alpha is critical for cytokineinduced gene expression. Nature 2003; 423: 655-659 [PMID: 12789342 DOI: 10.1038 /nature01576]
85. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557-561 [PMID: 17361131]
86. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-Associated cancer. Cell 2004; 118: 285-296 [PMID: 15294155]
87. Li Q, Yu YY, Zhu ZG, Ji YB, Zhang Y, Liu BY, Chen XH, Lin YZ. Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines. Eur Surg Res 2005; 37: 105-110 [PMID: 15905616]
88. Liu T, Liu D, Li u J, Song JT, Gao SL, Li H, Hu LH, Liu BR. Effect of NF-?B inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29. Exp Ther Med 2012; 4: 716-722 [PMID: 23170132 DOI: 10.38 92/etm.2012.647]
89. Li J, Minnich DJ, Camp ER, Brank A, Mackay SL, Hochwald SN. Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. J Surg Res 2006; 132: 112-120 [PMID: 16337965 DOI: 10.1016/j.jss.2005.10.005]
90. Huang WC, Ju TK, Hung MC, Chen CC. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 2007; 26: 75-87 [PMID: 17434128 DOI: 10.1016/j.molcel.2007.02.019]
91. Wang Q, Wang X, Evers BM. Induction of cIAP-2 in human colon cancer cells t hrough PKC delta/NF-kappa B. J Biol Chem 2003; 278: 51091-51099 [PMID: 14527959 DOI: 10.1074/jbc. M306541200]
92. Kang HW, Kim JM, Cha MY, Jung HC, Song IS, Kim JS. Deguelin, an Akt i nhibitor, down-regulates NF-?B signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci 2012; 57: 2873-2882 [PMID: 22623043 DOI: 10.1007/s10620-012-2237-x]
93. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25903-25914 [PMID: 16847054]
94. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004; 24: 2875-2889 [PMID: 15024076]
95. Chang KY, Shen MR, Lee MY, Wang WL, Su WC, Chang WC, Chen BK. Epidermal growth factor-Activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway upregulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma. J Biol Chem 2009; 284: 9908-9916 [PMID: 19203995 DOI: 10.1074/jbc.M806210200]
96. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ, Rodríguez-Enríquez S, Moreno-Sánchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009; 9: 1084-1 101 [PMID: 19689405]
97. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 200 7; 53: 233-256 [PMID: 17595539 DOI: 10.1159/000104457]
98. Jo JO, Kim SR, Bae MK, Kang YJ, Ock MS, Kleinman HK, Cha HJ. Thymosin ?4 induces the expression of vascular endothelial growth fa ctor (VEGF) in a hypoxia-inducible factor (HIF)-1?-dependent manner. Biochim Biophys Acta 2010; 1803: 1244-1251 [PMID: 20691219 DOI: 10.1016/j.bbamcr.2010.07.005]
99. Kitajima Y, Ide T, Oh tsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 2008; 99: 1341-1347
100. Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 2007; 1 21: 276-283 [PMID: 17372907 DOI: 10.1002/ijc.22679]
101. Stiehl DP,Bordoli MR,Abreu-Rodríguez I,Wollenick K,Schraml P,Gradin K,Poellinger L,Kristiansen G,Wenger RH. Non-canonica l HIF-2? function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop Oncogene 2012 31 2283-2297 PMID: 21927022 DOI: 10.1038/onc.2011.417]
102. Franovic A, Gun aratnam L, Smith K, Robert I, Patten D, Lee S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 2007; 104: 13092-13097 [PMID: 17670948]
103. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, Sotgia F, Lisanti MP. Metabolic reprogramming and two-compartment tu mor metabolism: opposing role(s) of HIF1? and HIF2? in tumorassociated fibroblasts and human breast cancer cells. Cell Cycle 2012; 11: 3280-3289 [PMID: 22894905 DOI: 10.4161/cc.21643]
104. Eberhart CE, Co ffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188 [PMID: 792 6468]
105. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789 [PMID: 7641194]
106. Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carl son CS, Casey G, Chang-Claude J, Chanock SJ, Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS, Giovannucci EL, Gong J, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M, Le Marchand L, Newcomb PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A, Schoen RE, Schumacher FR, Seminara D, Slattery ML, Thibodeau SN, Thomas F, Thornquist M, Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015; 313: 1133-1142 [PMID: 25781442 DOI: 10.1001/jama.2015.1815]
107. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293 [PMID: 11875501 DOI: 10.1038/nm0302-289]
108. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostagla ndin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-35457 [PMID: 12824187 DOI: 10.1074/jbc.M302474200]
109. Yu Z, Cui B, Jin Y, Chen H, Wang X. Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. Biochem Biophys Res Commun 2011; 411: 751-756 [PMID: 21782788 DOI: 10.1016/j.bbrc.2011.07.019]
110. Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y, Liu B, Zhu Z, Zhang J. Cetuximab inhibits ga stric cancer growth in vivo, independent of KRAS status. Curr Cancer Drug Targets 2014; 14: 217-224 [PMID: 24467518]
111. Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci USA 2012; 109: 7776-7781 [PMID: 22547830 DOI: 10.1073/pnas.1111135109]
112. Shant J, Cheng K, Marasa BS, Wang JY, Raufman JP. Aktdependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res 2009; 315: 432-450 [PMID: 19056378 DOI: 10.1016/j.yexcr.2008.11.003]
113. Feng Y, Dai X, Li X, Wang H, Liu J, Zhang J, Du Y, Xia L. EGF signalling pathway regulates colon cancer stem cell proliferation and apoptos is. Cell Prolif 2012; 45: 413-419 [PMID: 22925500 DOI: 10.1111/j.1365-2184.2012.00837.x]
114. Heeg S, Hirt N, Queisser A, Schmieg H, Thaler M, Kunert H, Quante M, Goesse l G, von Werder A, Harder J, Beijersbergen R, Blum HE, Nakagawa H, Opitz OG. EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-Alpha in a cel lular model of oral-esophageal carcinogenesis. Cancer Sci 2011; 102: 351-360 [PMID: 21156006 DOI: 10.1111/j.1349-7006.2010.01796.x]
115. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, X ia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 2011; 28 Suppl 1: S197-S203 [PMID: 21080109 DOI: 10.100 7/s12032-010-9696-8]
116. Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 2 012; 100: 156-163 [PMID: 21607591 DOI: 10.1007/s10266-011-0033-2]
117. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by E GFR independent of its kinase activity. Cancer Cell 2008; 13: 385-393 [PMID: 18455122 DOI: 10.1016/j.ccr.2008.03.015]
118. Ren J, Bollu LR, Su F, Gao G, Xu L, Huang WC, Hung MC, Weihua Z. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate 2013; 73: 1453-1461 [PMID: 23765757 DOI: 10 .1002/pros.22692]
119. Seiden-Long IM, Brown KR, Shih W, Wigle DA, Radulovich N, Jurisica I, Tsao MS. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorect al cancer. Oncogene 2006; 25: 91-102 [PMID: 16158056 DOI: 10.1038/sj.onc.1209005]
120. Seneviratne D, Ma J, Tan X, Kwon YK, Muhammad E, Melhem M, DeFrances MC, Zarnegar R. Genomic instability causes HGF gene activation in colon cancer cells, promoting their resistance to necroptosis. Gastroenter ology 2015; 148: 181-191.e17 [PMID: 25244939 DOI: 10.1053/j.gastro.2014.09.019]
121. Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y, Qu X. Cetuximabinduced MET activation acts a s a novel resistance mechanism in colon cancer cells. Int J Mol Sci 2014; 15: 5838-5851 [PMID: 24714091 DOI: 10.3390/ijms15045838]
122. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003; 63: 770 8-7716 [PMID: 14633695]
123. Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P. Selective disruption of insulin-like growth factor-1 ( IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem 2010; 285: 6563-6572 [PMID: 20044479 DOI: 10.1074/jbc.M109.097410]
124. Fleming SE, Zambell KL, Fitch MD. Glucose and glutamine provide similar proportions of energy to mucosal cells of rat small intestine. Am J Physiol 1997; 273: G968-G978 [PMID: 9357843]
125. Hild yard JC, AmmäläC, Dukes ID, Thomson SA, Halestrap AP. Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier. Biochim Biophys Acta 2005; 1707: 221-230 [PMID: 15863100]
126. Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, Kunji ER, Martinou JC. Identification and functional expression of the mitochondrial pyruva te carrier. Science 2012; 337: 93-96 [PMID: 22628554]
127. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209: 211-215 [PMID: 22330683]
128. de Wit M, Jimenez CR, Carvalho B, Belien JA, Delis-van Diemen PM, Mongera S, Piersma SR, Vikas M, Navani S, Pontén F, Meijer GA, Fijneman RJ. Cell surface proteomics identifi es glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression. Gut 2012; 61: 855-864 [PMID: 21890811]
129. Wincewicz A, Baltaziak M, Kanczuga-Koda L, Koda M, Sulkowska U, Sulkowski S. GLUT1 and Bcl-xL in relation to erythropoietin in human colorectal adenocarcinomas. Hepatogastroenterology 2010; 57: 741-745 [PMID: 21033220]
130. Ha TK, Chi SG. CAV1/caveolin 1 enhances aerobic glycolysis in colon cancer cells via activation of SLC2A3/GLUT3 transcription. Autophagy 2012; 8: 1684-1685 [PMID: 22874559 DOI: 10.4161/auto.21487]
131. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A, Simone C. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1a lpha-to FoxO-dependent transcription. Cell Death Differ 2009; 16: 1203-1214 [PMID: 19343039]
132. Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY, Park JG. Upregulation of g lycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009; 30: 2182-2192 [PMID: 19582719 DOI: 10.1002/elps.200800806]
133. Martinez-Balibrea E, Plasencia C, Ginés A, Martinez-Cardús A, Musulén E, Aguilera R, Manzano JL, Neamati N, Abad A. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal can cer and in human cell lines. Mol Cancer Ther 2009; 8: 771-778 [PMID: 19372549 DOI: 10.1158/1535-7163.MCT-08-0882]
134. Chou CW, Wu MS, Huang WC, Chen CC. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 2011; 6: e18087 [PMID: 21464950 DOI: 10.1371/journal. pone.0018087]
135. Ma YS, Yang IP, Tsai HL, Huang CW, Juo SH, Wang JY. High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells. DNA Cell Biol 2014; 33: 64-72 [PMID: 24283362 DOI: 10.1089/dna.2013.2161]
136. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007; 59: 495-505 [PMID: 16906425 DOI: 10.1007/s00280-006-0291-9]
137. Xuan Y, Hur H, Ham IH, Yun J, Lee JY, Shim W, Kim YB, Lee G, Han SU, Cho YK. Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of gl ucose metabolism. Exp Cell Res 2014; 321: 219-230 [PMID: 24342832 DOI: 10.1016/j.yexcr.2013.12.009]
138. Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor ef fect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol 2011; 2011: 740564 [PMID: 21403907 DOI: 10.1155/2011/740564]
139. Sánchez-Aragó M, Cuezva JM. The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 2011; 9: 19 [PMID: 21303518 DOI: 10.1186/1479-5876-9-19]
140. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH, Huang P. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway . Cell Death Differ 2014; 21: 124-135 [PMID: 24096870 DOI: 10.1038/cdd.2013.131]
141. Chen B, Liu Y, Jin X, Lu W, Liu J, Xia Z, Yuan Q, Zhao X, Xu N, Liang S. MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells. BMC Cancer 2014; 14: 443 [PMID: 24935220 DOI: 10.1186/1471-2407-14-443]
142. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, McQuade MM, Garner C, Digman MA, Teitell MA, Edwards RA, Gratton E, Waterman ML. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colo n cancer. EMBO J 2014; 33: 1454-1473 [PMID: 24825347 DOI: 10.15252/embj.201488598]
143. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-ind ucible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283: 28106-28114 [PMID: 18718909 DOI: 10.1074/jbc.M803508200]
144. Schell JC,Olson KA,Jiang L,Hawkins AJ,Van Vranken JG,Xie J,Egnatchik RA,Earl EG,DeBerardinis RJ,Rutter J. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth Mol Cell 2014 56 400-413 PMID: 25458841 DOI: 10.1016/j.molcel.2014.09.026]
145. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel s trategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-621 [PMID: 15695406]
146. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widger W, Ellis LM, Weihua Z. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012; 72: 304-314 [P MID: 22084398]
147. Kao KK, Fink MP. The biochemical basis for the antiinflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol 2010; 80: 151-159 [PMID: 20230800 DOI: 10.1016/j.bcp.2010.03.007]
148. Tian Y, Wang K, Wang Z, Li N, Ji G. Chemopreventive effect of dietary glutamine on colitis-Associated colon tumorigenesis in mice. Carcinogenesis 2013; 34: 1593-1600 [PMID: 23471883 DOI: 10.1093/carcin/bgt088]
149. Martín-Villa JM, Ferre-López S, López-Suárez JC, Corell A, Pérez-Blas M, Arnaiz-Villena A. Cell surface phenotype and ultramicros copic analysis of purified human enterocytes: a possible antigen-presenting cell in the intestine. Tissue Antigens 1997; 50: 586-592 [PMID: 9458111]
150. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T. High expression of Tolllike receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010; 102: 90 8-915 [PMID: 20145615]
151. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbarama iah K, Cooper HS, Itzkowitz SH, Abreu MT. Tolllike receptor-4 promotes the development of colitis-Associated colorectal tumors. Gastroenterology 2007; 133: 1869-1881 [PMID: 18054559]
152. Tan g X, Zhu Y. TLR4 signaling promotes immune escape of human colon cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Oncol Res 2012; 20: 15-24 [PMID: 23035361]
153. Tang XY , Zhu YQ, Wei B, Wang H. Expression and functional research of TLR4 in human colon carcinoma. Am J Med Sci 2010; 339: 319-326 [PMID: 20228668 DOI: 10.1097/MAJ.0b013e3181cef1b7]
154. Ruemmele FM, Beaulieu JF, Dionne S, Levy E, Seidman EG, Cerf-Bensussan N, Lentze MJ. Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tu mour necrosis factor alpha. Gut 2002; 51: 842-848 [PMID: 12427787]
155. Grondin V, Seksik P, Dumont S, Thomas G, Trugnan G, Fléjou JF, Masliah J, Wendum D, Bachelet M. Reg ulation of colon cancer cell proliferation and migration by MD-2 activity. Innate Immun 2011; 17: 414-422 [PMID: 20699280]
156. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127 [PMID: 17615359]
157. Santaolalla R, Sussman DA, Ruiz JR, Davies JM, Pastorini C, España CL, Sotolongo J, Bu rlingame O, Bejarano PA, Philip S, Ahmed MM, Ko J, Dirisina R, Barrett TA, Shang L, Lira SA, Fukata M, Abreu MT. TLR4 activates the ?-catenin pathway to cause intestinal neoplasia. PLoS One 2013; 8: e63298 [PMID: 23691015 DOI: 10.1371/journal.pone.0063298]
158. Kuo WT, Lee TC, Yang HY, Chen CY, Au YC, Lu YZ, Wu LL, Wei SC, Ni YH, Lin BR, Chen Y, Tsai YH, Kung JT, Sheu F, Lin LW, Yu LC. LPS receptor subunits have antagonistic roles in epithelial apoptosis and colonic carcinogenesis. Cell Death Differ 2015; 22: 1590-1604 [PMID: 25633197 DOI: 10.1038/cdd.2014.240]
159. Vander Heiden MG. Exploiting tumor metabolism: challenges for clinical translation. J Clin Invest 2013; 123: 3648-3651 [PMID: 23999437 DOI: 10.1172/JCI72391]
160. Song L, Li Y, He B, Gong Y. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer. Clin Colorectal Cancer 2015; 14: 133-145 [PMID: 25799881 DOI: 10.1016/j.clcc.2 015.02.001]